To evaluate whether drugs for metabolic conditions influence prostate cancer-specific mortality in men starting gonadotrophin-releasing hormone (GnRH) agonists, as it is unclear whether metabolic syndrome and its related drugs is affecting treatment response in men with prostate cancer on GnRH agonists.
Objective
To evaluate whether drugs for metabolic conditions influence prostate cancer-specific mortality in men starting gonadotrophin-releasing hormone (GnRH) agonists, as it is unclear whether metabolic syndrome and its related drugs is affecting treatment response in men with prostate cancer on GnRH agonists.
Patients and Methods
We selected all men receiving GnRH agonists as primary treatment in the Prostate Cancer data Base Sweden (PCBaSe) (n = 9267). Use of drugs for metabolic conditions (i.e. antidiabetes, anti-dyslipidaemia, and antihypertension) in relation to all-cause, cardiovascular disease (CVD), and prostate cancerspecific death were studied using multivariate Cox proportional hazard and Fine and Gray competing regression models.
Results
In all, 6322 (68%) men used at least one drug for a metabolic condition at GnRH agonist initiation: 46% on antihypertensive drugs only, 32% on drugs for dyslipidaemia and hypertension, and~10% on drugs for more than two metabolic conditions. Cox models indicated a weak increased risk of prostate cancer death in men who were on drugs for hypertension only (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.03-1.23) or drugs for hyperglycaemia (HR 1.19, 95% CI 1.06-1.35) at GnRH agonist initiation. However, upon taking into account competing risk from CVD death, none of the drugs for metabolic conditions were associated with an increased risk of prostate cancer death.
Introduction
A recent meta-analysis estimated that the risk of prostate cancer is 1.54-times (95% CI 1.23-1.94) higher for those with metabolic syndrome (MetS), as compared to those without MetS [1] . Recent studies also suggest that the presence of MetS or some of its features is associated with higher grade disease in men with prostate cancer and can lead to more rapid progression [2, 3] . In contrast, drugs that treat components of MetS (e.g. metformin for diabetes or statins for dyslipidaemia) have also been associated with a reduced risk and progression of prostate cancer [4] [5] [6] [7] . However, the underlying biological mechanisms for these observations have not been fully elucidated [8] .
GnRH agonists are associated with an increased risk of type 2 diabetes, as well as other components of the MetS in men with prostate cancer who are treated with androgendeprivation therapy (ADT) [9] . Moreover, one recent study found that having MetS may shorten time to castrateresistant prostate cancer and overall survival [3] , whereas another study did not find any statistically significant associations between baseline MetS and prostate cancer death [10] .
of GnRH agonist initiation may affect response to treatment by studying time to prostate cancer death.
Patients and Methods
We selected all men with prostate cancer who received primary GnRH agonists between 2007 and 2013 (n = 9267), as registered in the Prostate Cancer data Base Sweden (PCBaSe) Traject, which is described in detail elsewhere [11, 12] . Briefly, the PCBaSe was created by linking the Swedish National Prostate Cancer Register (NPCR) with a number of other population-based registers using the Swedish personal identity number for record linkage. The Research Ethics Board at Ume a University approved this study [12] .
Based on the underlying causes of death registered in the Cause of Death Register, the following main outcomes were defined for this study: death from prostate cancer (International Classification of Diseases-10 [ICD-10] code: C61), death from cardiovascular disease (CVD; ICD-10: I10-I99), as well as other deaths (remaining ICD-10 codes), and overall mortality [13] .
The main exposure variables for this study were newly filled prescriptions, prescribed before GnRH agonist initiation, for treatment of diabetes (metformin, sulphonylurea, insulin), dyslipidaemia (statins), hypertension (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, b-blockers, calcium channel blockers, or thiazide and thiazide-like diuretics), or anti-obesity agents in the Prescribed Drug Register. As only 20 men received anti-obesity agents, exposure to these drugs was not considered as part of the analysis a priori. As many men often take drugs for more than one of the metabolic conditions listed above, we looked at each metabolic drug group individually, as well as the most common combinations: dyslipidaemia only (n = 241), hyperglycaemia only (n = 67; 38 on insulin and 29 on metformin or sulphonylurea), hypertension only (n = 2933), dyslipidaemia and hyperglycaemia (n = 41), dyslipidaemia and hypertension (n = 1996), hyperglycaemia and hypertension (n = 333), and treated for more than two metabolic conditions (n = 651). The analyses focused on the four most common groups of drugs: hypertension only, hypertension and dyslipidaemia, any hyperglycaemia, dyslipidaemia only (Fig. 1) .
The following information on potential covariates was also obtained: age, tumour grade and stage and educational level. Prostate cancer risk category was defined according to a modification of the National Comprehensive Cancer Network Guideline [14] : low risk: T1-2, Gleason score of 2-6 and PSA level of <10 ng/mL; intermediate risk: T1-2, Gleason score of 7 and/or PSA level of 10-20 ng/mL; high risk: T3 and/or Gleason score of 8-10 and/or PSA level of 20-50 ng/mL; regionally metastatic/locally advanced: T4 and/or N1 and/or PSA level of 50-100 ng/mL in the absence of distant metastases (M0 or MX); and distant metastases: M1 and/or PSA level of >100 ng/mL. In addition, we collected information on history of CVD, defined by any CVD hospital admission (ICD-10 codes: I20-I25, I50, I60-I69, I70-I79) as primary diagnoses in the National Patient Register. Comorbidities were also measured using the Charlson Comorbidity Index (CCI), which assigns weights to a number of medical conditions. Each condition was assigned a score of 1, 2, 3 or 6, and the final CCI was the sum of these scores [15] . Individuals were grouped into CCI categories for final scores of 0, 1, 2 or ≥3. History of CVD and CCI were included for descriptive purposes, as careful assessment of the causal pathway did not indicate that these covariates need to be included in multivariate models ( Fig. 2) [16] . The use of a directed acyclic graph (DAG) helps represent causal relations among variables to determine which ones need to be controlled for in the estimation of causal effects [17] .
Statistical analysis
We conducted univariate and multivariate Cox proportional hazard regression models to assess the association between individual metabolic drugs, as well as common combinations ( Fig. 2 ) and death from prostate cancer, CVD, and overall mortality. Multivariate models were adjusted for age, education level, disease stage, and civil status. Adjustments for age were done using natural cubic splines with four degrees of freedom. To consider competing risks, we repeated the analyses using Fine and Gray competing risk regression [18] . As all the men were on primary GnRH agonists and disease stage was taken into account, all analyses are based on the intention-to-treat assumption, i.e., all men stayed on ADT, which was the standard drug for advanced prostate cancer in Sweden at the time of data collection.
To further illustrate the associations between metabolic drugs and causes of death, stacked cumulative incidence proportion functions for all-cause, CVD, and prostate cancer-specific death were displayed by categories of metabolic drug use.
Data management was performed using the Statistical Analysis System (SAS), version 9.3 (SAS Institute, Cary, NC, USA) and data analysis was conducted with R version 2.13.2 (R Foundation for Statistical Computing, Wien, Austria).
Results
In all, 6322 (68%) men used at least one drug for a metabolic condition at the time they started GnRH agonists. Most of these men were on antihypertensive drugs only (46%), followed by men on drugs for dyslipidaemia and hypertension (32%). About 10% of men were on drugs for more than two metabolic conditions. Table 1 shows the baseline characteristics of all men included in the study based on the type of metabolic drugs they were taking at time of GnRH agonist initiation.
Multivariate Cox proportional hazards regression adjusted for age, education, and prostate cancer risk category showed that use of most metabolic drugs were associated with an increased risk of CVD death and hence also overall death (Table 2 ). For instance, those men on antihypertensive drugs only were 1.87-times more likely to die from CVD than men not taking any metabolic drugs (95% CI 1.56-2.24) and this increased to 2.46-times if these men were also taking drugs for dyslipidaemia (95% CI 2.03-2.98). For prostate cancer death, there was a small increased risk for those on drugs for hypertension only or any hyperglycaemia (hazard ratio [HR] 1.12, 95% CI 1.03-1.23); and HR 1.19, 95% CI 1.06-1.35, respectively).
Given the strong association with death from CVD, competing risk regression showed little impact on the association between metabolic drugs and death from CVD (Table 2) . However, the associations seen for prostate cancer death disappeared and even became inverse for those on drugs for hypertension and dyslipidaemia, although not statistically significant (HR 0.92, 95% CI 0.83-1.02). Figure 3 shows these findings using stacked cumulative incidence proportions. The largest proportion of CVD-deaths (red) can be seen amongst those on metabolic drugs, with the biggest proportion for those who are on drugs for both hypertension and statins. The proportion of prostate cancer deaths (blue) was fairly similar across all the groups studied. 
Discussion
Traditional Cox proportional hazards models indicated a weak increased risk of prostate cancer death in men who are on drugs for hypertension or hyperglycaemia at the time they start GnRH agonists. However, upon taking into account competing risk from CVD death none of the drugs for metabolic conditions were associated with an increased risk of prostate cancer death and a trend towards an inverse association was seen for those who were on drugs for both hypertension and dyslipidaemia.
To our knowledge, few studies have investigated the effect of drugs for metabolic conditions in relation to response to treatment for men on GnRH agonists [19] . Most studies to date have explored the effect of single drugs, predominantly metformin, statins, or b-blockers, in relation to prostate cancer death [5, [20] [21] [22] [23] [24] [25] [26] [27] . Moreover, these existing observational studies have found contradicting results and they did not specifically study those men on GnRH agonists, a drug that in itself is also associated with an increased risk of metabolic conditions [9] . Some reasons for these contrasting findings have been summarised previously [7] , but by investigating several drugs for metabolic conditions in a specifically defined group of men with prostate cancer, the present study aimed to improve our understanding of possible metabolic drug effects in the context of prostate cancer progression.
Thus, to our knowledge the present study is the first to specifically investigate the overall use of drugs for metabolic conditions and prostate cancer death in men on GnRH agonists. Our present results are consistent with a small study (n = 273) investigating the effect of MetS (without looking at the related drugs) on prostate cancer death in men on ADT using data from the Health Professionals Follow-up Study and the Veteran's Administration [10] . The authors concluded that there was no association of prostate cancerspecific death and MetS, but the latter was associated with an increased risk of death from all causes. However, there was a weak positive association between hypertension only and prostate cancer-specific death (HR 1.59, 95% CI 0.89-2.84). Although the exposure assessment in that study was different from what we have done here, none of the studies support a strong association between metabolic aberrations and prostate cancer-specific death in men on GnRH agonists. The latter is relevant from a clinical point of view and could inform future studies looking into how development and treatment of MetS after initiation of GnRH agonists (as an adverse event) may affect response to hormonal treatment or prostate cancer progression.
A major strength of our present study is the use of comprehensive data in the PCBaSe Traject, a large nationwide population-based register from which information on complete follow-up, prostate cancer treatment, prostate cancer risk category, comorbidities, and socio-economic status can be retrieved. As with other currently published studies, our follow-up was rather short and a follow-up study might provide more power to investigate risk of prostate cancer death in a competing risk setting (e.g. death from CVD [28] ). Another limitation of the present study is the lack of direct measures of MetS (e.g. serum glucose and cholesterol levels [7] ) and information on ethnicity or lifestyle factors. However, the latter could be approximated by the CCI, which was not needed as a covariate in the statistical models (Fig. 2) .
Conclusion
Despite the suggested complex interaction between MetS, metabolic drugs, and prostate cancer progression, the present study did not find any evidence for a better or worse response to GnRH agonists in men who were also on drugs for hypertension, dyslipidaemia, or hyperglycaemia. These findings suggest that treatment of MetS is important in men on GnRH agonists, but not a contraindication for their prostate cancer treatment.
